CD36 Monoclonal antibody

CD36 Monoclonal Antibody for IHC, WB,ELISA

Host / Isotype

Mouse / IgG1









Cat no : 66395-1-Ig


CD36, CHDS7, FAT, Fatty acid translocase, Glycoprotein IIIb, GP3B, GP4, GPIIIB, GPIV, PAS 4, PAS IV, PASIV, Platelet collagen receptor, Platelet glycoprotein 4, Platelet glycoprotein IV, SCARB3, Thrombospondin receptor

Tested Applications

Positive WB detected inhuman heart tissue, human milk, human spleen tissue, human placenta tissue
Positive IHC detected inhuman spleen tissue, human heart tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:1000-1:6000
Immunohistochemistry (IHC)IHC : 1:500-1:2000
Sample-dependent, check data in validation data gallery

Product Information

66395-1-Ig targets CD36 in WB, IHC,ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivity human
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen CD36 fusion protein Ag13541
Full Name CD36 molecule (thrombospondin receptor)
Calculated molecular weight 472 aa, 53 kDa
Observed molecular weight 88 kDa
GenBank accession numberBC008406
Gene symbol CD36
Gene ID (NCBI) 948
Conjugate Unconjugated
Form Liquid
Purification Method Protein G purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information


CD36, also known as platelet glycoprotein 4, is an integral membrane glycoprotein that acts as a scavenger receptor. CD36 can bind to multiple ligands, including thrombospondin-1, collagen, oxidized phospholipids, oxidized low-density lipoprotein, and long-chain fatty acids. CD36 can also bind to erythrocytes parasitized by Plasmodium falciparum and apoptotic cells. CD36 mediates different biological processes, acting as a signaling hub in angiogenesis, inflammatory response, and fatty acid metabolism.

Tissue specificity

CD36 is present on the surface of various cells types, such as adipocytes, monocytes, macrophages, platelets, microvascular endothelial cells, dendritic cells, and hematopoietic precursors of red cells.

Involvement in disease
  • Mutations in CD36 can give rise to platelet glycoprotein IV deficiency, a type of macrothrombocytopenia.

  • Polymorphisms in CD36 can increase susceptibility to malaria.

  • AAGIC haplotype at the CD36 locus increases the risk of coronary heart disease.

  • Disruption of CD36-dependent pathways and certain SNPs in the CD36 gene are attributed to impaired fatty acid metabolism, glucose intolerance, Alzheimer’s disease, atherosclerosis, arterial hypertension, diabetes, and cardiomyopathy.


Apart from the full-length protein (isoform 1), one additional shorter isoform has been reported (PMID: 7509795). Other alternative isoforms have also been detected on the mRNA level (PMID: 17673938).

Post-translational modifications

The extracellular domain of CD36 is extensively glycosylated. Glycosylation is needed for the transport of CD36 to the plasma membrane, as well as mediating recognition and binding to ligands. Cytoplasmic tails of transmembrane domains can be phosphorylated and play a role in signal transduction. Intracellular domains can be additionally acetylated, ubiquitinated, and palmitoylated (PMID: 28919632).

Cellular localization

CD36 is present on the cell surface.            


Product Specific Protocols
WB protocol for CD36 antibody 66395-1-IgDownload protocol
IHC protocol for CD36 antibody 66395-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols



J Appl Physiol (1985)

Molecular adaptations in human subcutaneous adipose tissue after ten weeks of endurance exercise training in healthy males.

Authors - Simon Riis

Physiol Rep

Redundancy in regulation of lipid accumulation in skeletal muscle during prolonged fasting in obese men.

Authors - Morten L Høgild

Scand J Med Sci Sports

Acute and sustained effects of a periodized carbohydrate intake using the sleep-low model in endurance-trained males.

Authors - Simon Riis